ReviewDrugs2005
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 80 citations in OpenAlex.
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.European journal of clinical pharmacology · 2009Trial
- Molecular Targeted Therapy for Chronic Non-Bacterial Mastitis: New Insights into Pathophysiology and Therapeutic Strategies.International journal of women's health · 2026Review
- Article
- Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study.Antioxidants (Basel, Switzerland) · 2022Article
- Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU.Clinical drug investigation · 2021Review
- Article
- Inflammation associated with noise-induced hearing loss.The Journal of the Acoustical Society of America · 2019Review
- T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis.Frontiers in immunology · 2018Article
- Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study.Frontiers in pharmacology · 2017Article
- Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.Clinical and experimental immunology · 2016Article
- How the immune system responds to therapeutic biological agents.The Journal of international medical research · 2016Article
- Immune system of the inner ear as a novel therapeutic target for sensorineural hearing loss.Frontiers in pharmacology · 2014Review
- Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition.Clinical and experimental immunology · 2011Article
- Article
- Infliximab in ulcerative colitis.Biologics : targets & therapy · 2008Article
- A trans-Golgi network golgin is required for the regulated secretion of TNF in activated macrophages in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFalpha.The Journal of cell biology · 2007Article
- Infliximab in the treatment of Crohn's disease.Therapeutics and clinical risk management · 2007Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infliximab (Remicade) is a chimeric monoclonal antibody against tumour necrosis factor (TNF)-alpha that has shown efficacy in Crohn's disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with initial infusions at 0, 2 and 6 weeks, followed by administration once every 8 weeks. Infliximab is effective in the treatment of patients with moderately to severely active Crohn's disease with an inadequate response to other treatment options or those with fistulising disease. In combination with methotrexate, infliximab reduced signs and symptoms and delayed disease progression in patients with active, methotrexate-refractory rheumatoid arthritis and in those with early disease. The drug was generally well tolerated. Recrudescence of tuberculosis infection and worsening of heart failure and demyelinating disease are among some of the concerns with anti-TNFalpha therapy, requiring cautious use of these agents in high-risk patients. Current data suggest that infliximab may be cost effective, especially when long-term clinical outcomes and burden of the diseases are taken into account. More robust, prospective pharmaco-economic studies are required to better ascertain the cost effectiveness of infliximab. Direct head-to-head comparative trials of infliximab with other biological agents are not yet available and would be helpful in determining with greater certainty the place of infliximab in the management of these diseases. Nonetheless, infliximab, like other biological agents, is a valuable treatment option in patients with moderately to severely active Crohn's disease (including fistulising disease) or rheumatoid arthritis (including early disease).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.